LIVERFASt outperforms FIB-4, in sequential combination with VCTE, for identifying ≥F3 stages in MASLD including T2DM
LIVERFASt outperforms FIB-4, in sequential combination with VCTE, for identifying ≥F3 stages in MASLD including T2DM
LIVERFASt outperforms FIB-4, in sequential combination with VCTE, for identifying ≥F3 stages in MASLD including T2DM
Dynamics of NITs (LIVERFASt, FIB-4, VCTE) during monitoring therapy with Resmetirom in patients with MASH — update
Noninvasive initiation and monitoring of Resmetirom therapy using LIVERFASt, FIB-4 and VCTE in patients with MASH
Correlations between LIVERFASt, MRE for fibrosis assessment and ICFF for steatosis assessment in MASLD patients
The utility of NITs — LIVERFASt, FIB-4 and VCTE — in the initiation and monitoring of Resmetirom therapy in MASH patients (initial cohort)
Diagnostic performance of LIVERFASt as a non-invasive liver fibrosis test: data from three cohorts (JGLD manuscript)
Combination of LF and LSM using Fibroscan outperforms FIB-4 and LSM in patients with T2D
Association between Psoriasis severity and steatosis measured by LIVERFASt
Comparison of prevalence of advanced fibrosis using LiverSTAT or FIB-4 combined with LSM/VCTE in a prospective chronic liver disease cohort (Mongolia)
Combination of LIVERSTAT and Fibroscan-LSM outperforms FIB-4 and LSM for MASLD Advanced Fibrosis (F3F4) — multicenter